NEW YORK, Jan. 30, 2018 /PRNewswire/ --WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on BIVV, BMRN, BPMC, and CXRX which can be accessed for free by signing up to www.wallstequities.com/registration. On Monday, the NASDAQ Composite ended the day at 7,466.51, down 0.52%; the Dow Jones Industrial Average
Waltham, Massachusetts headquartered Bioverativ Inc.'s stock finished Monday's session 0.13% lower at $102.90 with a total trading volume of 3.42 million shares, which was above its three months average volume of 2.00 million shares. The stock has gained 89.75% in the past month, 79.74% over the past three months, and 130.30% in the previous twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 73.37% and 76.98%, respectively. Moreover, shares of Bioverativ, which focuses on the research, discovery, development, and commercialization of therapies for the treatment of hemophilia and other blood disorders in the US and Japan, have a Relative Strength Index (RSI) of 92.81.
On January 24th, 2018, research firm Argus downgraded the Company's stock rating from 'Buy' to 'Hold'. Get the full research report on BIVV for free by clicking below at:
Shares in San Rafael, California headquartered BioMarin Pharmaceutical Inc. rose 0.69%, ending yesterday's session at $92.23 with a total trading volume of 1.23 million shares. The stock has gained 11.75% in the previous three months. The Company's shares are trading above their 50-day and 200-day moving averages by 5.34% and 3.67%, respectively. Moreover, shares of BioMarin Pharma, which develops and commercializes pharmaceuticals for serious diseases and medical conditions in the US, Europe, Latin America, and internationally, have an RSI of 60.18.
On January 18th, 2018, research firm Credit Suisse resumed its 'Outperform' rating on the Company's stock, with a target price of $113 per share. Gain free access to the research report on BMRN at:
On Monday, Cambridge, Massachusetts headquartered Blueprint Medicines Corp.'s stock saw a rise of 0.12%, to close the day at $83.11. A total volume of 192,236 shares was traded. The Company's shares have advanced 23.03% in the previous three months and 139.92% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 10.55% and 43.24%, respectively. Additionally, shares of Blueprint Medicines, which develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases, have an RSI of 56.69. Register for your free report coverage on BPMC at:
Shares in Oakville, Canada headquartered Concordia International Corp. ended the day 5.28% lower at $0.72. A total volume of 159,406 shares was traded. The stock has gained 25.72% in the last month and 21.91% in the previous three months. The Company's shares are trading above their 50-day moving average by 16.24%. Furthermore, shares of Concordia, which owns a portfolio of branded and generic prescription products in the US and internationally, have an RSI of 53.06. Get the free research report on CXRX at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute
View original content:http://www.prnewswire.com/news-releases/biotech-stocks-research-reports-released-on-bioverativ-biomarin-pharma-blueprint-medicines-and-concordia-intl-300590130.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All